EP1198755A2 - Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique - Google Patents

Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique

Info

Publication number
EP1198755A2
EP1198755A2 EP00950944A EP00950944A EP1198755A2 EP 1198755 A2 EP1198755 A2 EP 1198755A2 EP 00950944 A EP00950944 A EP 00950944A EP 00950944 A EP00950944 A EP 00950944A EP 1198755 A2 EP1198755 A2 EP 1198755A2
Authority
EP
European Patent Office
Prior art keywords
costs
population
disease management
user
benefits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00950944A
Other languages
German (de)
English (en)
Inventor
Zeba Mohammad Glaxo Wellcome Inc. KHAN
Peggy Sue Glaxo Wellcome Inc. OLSON
Teresa Lynn Glaxo Wellcome Inc. YOUNG
Michael T. Halpern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1198755A2 publication Critical patent/EP1198755A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G06COMPUTING; CALCULATING OR COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00Administration; Management
    • G06Q10/10Office automation; Time management
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Definitions

  • Another scenario in which it may be desirable to have an efficient method of calculating the costs and benefits of a disease management intervention is in marketing such a program or product associated with the intervention to an employer or a health plan provider.
  • a pharmaceuticals manufacturer may wish to market a drug associated with a disease management intervention to employers or health plan providers.
  • the manufacturer may wish to present a cost- benefit analysis relating to the drug to the employer or health plan provider.
  • This analysis may include calculating incremental costs and benefits of the intervention over a period of time using employer- or health plan-specific data.
  • These calculations may be complex and typically require the hiring of an actuarial consulting firm. Hiring an actuarial consulting firm may be expensive and impractical because the firm would be required to be hired to perform the cost-benefit analysis for each employer or health plan provider.
  • Figure 12 illustrates a benefit-cost analysis window according to an embodiment of the present invention
  • the program may include an initial window 200.
  • the initial window 200 may allow the user to edit an existing scenario or to create a new scenario.
  • scenario refers to a computer file containing user-specified parameters or default parameters associated with the population being treated in a disease management intervention and parameters used to model the intervention.
  • the parameters window 202 may include a button or other graphical user interface that allows the user to access an intervention parameters window 216.
  • the intervention parameters window 216 allows the user to customize parameters of the disease management intervention, such as the level of promotion, the success rate, participation rates, and costs associated with the intervention.
  • default values may be displayed, and the user is preferably allowed to change the default values based on the specific parameters of the intervention being implemented.
  • one of the costs that the user may specify is the cost of a drug associated with the intervention. This cost may include the average wholesale price, the amount of co-payment, dispensing fee, etc. These costs may vary from one intervention to another. Thus, it may be desirable to allow the user to input different values.
  • the program assumes that employees/health plan members who leave prior to age 65 will be replaced by new employees/health plan members with the same age and gender.
  • the smoking status of the replacement employee/health plan member will be determined based on the distributions from the original model population (i.e., the smoking status distribution in the overall population, based on age, gender, occupation mix, and region of country), not the current distribution in the workforce or health plan when the employee/health plan member leaves.
  • a proportional number of adult dependents also leave (based on the proportion of the employees/health plan members to adult dependents).
  • the departing adult dependents will have the same age and opposite gender of the departing employees/health plan members.
  • the smoking status of the departing adult dependents will be based on the proportion of never/former/current smokers currently in the workforce/health plan for that gender and age cohort. Employees dying prior to age 65 will be replaced in a similar fashion.
  • the annual number of never smoker-induced abortions is also determined as the product of the annual number of pregnancies and the age-specific induced abortion rate.
  • the annual number of never smoker live births is the number of pregnancies minus the number of miscarriages and induced abortions.
  • the annual number of never smoker low birth weight infants is the product of the annual number of live births and the rate of low birth weights.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Human Resources & Organizations (AREA)
  • Strategic Management (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Marketing (AREA)
  • Quality & Reliability (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tourism & Hospitality (AREA)
  • General Physics & Mathematics (AREA)
  • Operations Research (AREA)
  • Economics (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés et des systèmes servant à estimer les coûts et avantages relatifs aux interventions de gestion thérapeutique, lesdits systèmes comprenant une interface graphique utilisateur au moyen de laquelle un utilisateur introduit des données spécifiques à une population destinée à être traitée (ou à laquelle un traitement serait proposé) dans le cadre d'une intervention de gestion thérapeutique. Les coûts et avantages relatifs à l'intervention de gestion thérapeutique sont projetés sur une population en rapport avec une période déterminée, et ce sur la base de données indiquées par l'utilisateur. Les coûts et avantages sont présentés à l'utilisateur afin de lui faciliter la tâche d'évaluation de l'impact économique de l'intervention de gestion thérapeutique.
EP00950944A 1999-08-02 2000-08-02 Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique Withdrawn EP1198755A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36600799A 1999-08-02 1999-08-02
US366007 1999-08-02
PCT/US2000/021106 WO2001009758A2 (fr) 1999-08-02 2000-08-02 Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique

Publications (1)

Publication Number Publication Date
EP1198755A2 true EP1198755A2 (fr) 2002-04-24

Family

ID=23441311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00950944A Withdrawn EP1198755A2 (fr) 1999-08-02 2000-08-02 Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique

Country Status (4)

Country Link
EP (1) EP1198755A2 (fr)
JP (1) JP2003522994A (fr)
AU (1) AU6397100A (fr)
WO (1) WO2001009758A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005050210A (ja) * 2003-07-30 2005-02-24 Mitsui Sumitomo Insurance Co Ltd 医療費予測システム、医療費予測サーバ、医療費予測方法、及びプログラム
JP4209830B2 (ja) * 2004-10-29 2009-01-14 三井住友海上火災保険株式会社 医療費予測システム、医療費予測サーバ、医療費予測方法、及びプログラム
WO2015190587A1 (fr) 2014-06-12 2015-12-17 塩野義製薬株式会社 Dérivé de macrolide de polyène
KR101876858B1 (ko) * 2017-03-13 2018-07-11 삼성화재해상보험 주식회사 질병 발현 예측 및 컨설팅 시스템
CN112420204B (zh) * 2020-11-03 2023-10-20 重庆医科大学 乳腺癌筛查方案推荐系统及推荐方法
JP7399336B1 (ja) * 2023-03-23 2023-12-15 DeSCヘルスケア株式会社 健康に関するデータを分析するためのシステム、方法、及びプログラム

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0109758A2 *

Also Published As

Publication number Publication date
JP2003522994A (ja) 2003-07-29
WO2001009758A2 (fr) 2001-02-08
WO2001009758A8 (fr) 2002-01-10
AU6397100A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
US7698155B1 (en) System for determining a disease category probability for a healthcare plan member
US20170316530A1 (en) Method and System for Providing Reports and Segmentation of Physician Activities
Sloan Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies
US8762169B2 (en) Medical value index
US5918208A (en) System for providing medical information
US7778846B2 (en) Sequencing models of healthcare related states
Fillenbaum et al. Factors predicting change in prescription and nonprescription drug use in a community-residing black and white elderly population
US20080243539A1 (en) Method and System for Exchanging, Storing, and Analyzing Health Information
US20060089862A1 (en) System and method for modeling benefits
US7844473B1 (en) System for allocating home health services
Sandier Health services utilization and physician income trends
US20090076857A1 (en) Systems and methods for managing patient pharmaceutical care
US20030065534A1 (en) Health care management method and system
US8676598B2 (en) Chronic population based cost model to compare effectiveness of preventive care programs
US7716069B2 (en) System and method for implementing medical risk algorithms at the point of care
Demir et al. A simulation tool for better management of retinal services
US20140316802A1 (en) System and method for evaluating healthcare information technology
EP1198755A2 (fr) Procedes informatises permettant d'estimer les couts et avantages relatifs aux interventions de gestion therapeutique
US20190304024A1 (en) Decision tool for use by individuals in healthcare plan selection
Oh et al. Scientific evaluation of polyclinic operating strategies with discrete-event simulation
Finkelstein et al. Patient assessments of hospital maternity care: a useful tool for consumers?
Mason et al. Using electronic health records to monitor and improve adherence to medication
Mariotti et al. Consensus among clinicians on referrals’ priority and use of digital decision-making support systems
Dewar et al. A Cost-Benefit Analysis of Mechanical Ventilation: An Examination of DRG 475
Sharkey et al. Opportunities and challenges in Medicaid managed care: The experience in Maryland

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030301